Based on this consideration and consistent with the previous studies which focused on AML chemoresistance [13, 14, 40], we included RR-AML patients with different genetic/FAB subtypes but received the same treatment regimens in this study. The gene discussed is FANCB; the disease is acute myeloid leukemia.